Literature DB >> 21494786

Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

Dafna D Gladman1, Vinod Chandran.   

Abstract

Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease associated with psoriasis, is a complex disease in terms of its clinical presentation, etiology, and pathogenesis. Musculoskeletal presentations include peripheral arthritis, spondylitis, enthesitis, and dactylitis. To learn about the course of and prognosis for such a complex disease, it is important to observe patients longitudinally so that all aspects of the disease are recognized. Several registries have been developed to evaluate the course of and prognosis for patients with PsA. Based on such registries, it has been shown that PsA is more severe than previously thought, and that progression of joint damage is related to joint inflammation. Such registries also have been used to determine genetic factors in PsA and to identify biomarkers for both susceptibility and expression of the disease. Drug registries also have been developed to document response to new therapies as well as the long-term adverse effects resulting from such therapies. It is hoped that an international effort currently on the way will further enhance the contribution of PsA patient registries to address the etiology, pathogenesis, and outcome of this complex disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494786     DOI: 10.1007/s11926-011-0182-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  43 in total

1.  Mortality in psoriatic arthritis - a single-center study from the UK.

Authors:  Caitriona Buckley; Charlotte Cavill; Gordon Taylor; Hazel Kay; Nicola Waldron; Eleanor Korendowych; Neil McHugh
Journal:  J Rheumatol       Date:  2010-08-03       Impact factor: 4.666

2.  Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis.

Authors:  J R Lambert; V Wright
Journal:  Q J Med       Date:  1977-10

3.  The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.

Authors:  M Shbeeb; K M Uramoto; L E Gibson; W M O'Fallon; S E Gabriel
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

4.  Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry.

Authors:  Soumya M Reddy; Allen P Anandarajah; Mark C Fisher; Philip J Mease; Jeffrey D Greenberg; Joel M Kremer; George Reed; Rui Chen; Susan Messing; Kimberly Kaukeinen; Christopher T Ritchlin
Journal:  J Rheumatol       Date:  2010-09-15       Impact factor: 4.666

5.  Ten years with biologics: to whom do data on effectiveness and safety apply?

Authors:  Julia F Simard; Elizabeth V Arkema; Anders Sundström; Pierre Geborek; Tore Saxne; Eva Baecklund; Lars Coster; Christina Dackhammar; Lennart Jacobsson; Nils Feltelius; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Lars Klareskog; Ronald F van Vollenhoven; Martin Neovius; Johan Askling
Journal:  Rheumatology (Oxford)       Date:  2010-11-16       Impact factor: 7.580

6.  Cardiovascular morbidity in psoriatic arthritis.

Authors:  D D Gladman; M Ang; L Su; B D M Tom; C T Schentag; V T Farewell
Journal:  Ann Rheum Dis       Date:  2008-08-12       Impact factor: 19.103

7.  Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease.

Authors:  S M Jones; J B Armas; M G Cohen; C R Lovell; G Evison; N J McHugh
Journal:  Br J Rheumatol       Date:  1994-09

8.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Authors:  Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.

Authors:  D Kane; L Stafford; B Bresnihan; O FitzGerald
Journal:  Rheumatology (Oxford)       Date:  2003-10-01       Impact factor: 7.580

10.  Prevalence of malignancy in psoriatic arthritis.

Authors:  Sherry Rohekar; Brian D M Tom; Agnes Hassa; Cathy T Schentag; Vernon T Farewell; Dafna D Gladman
Journal:  Arthritis Rheum       Date:  2008-01
View more
  5 in total

1.  Prevalence and treatment patterns of psoriatic arthritis in the UK.

Authors:  Alexis Ogdie; Sinéad Langan; Thorvardur Love; Kevin Haynes; Daniel Shin; Nicole Seminara; Nehal N Mehta; Andrea Troxel; Hyon Choi; Joel M Gelfand
Journal:  Rheumatology (Oxford)       Date:  2012-12-07       Impact factor: 7.580

2.  How can psoriatic arthritis be diagnosed early?

Authors:  Amir Haddad; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 3.  Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.

Authors:  Philip J Mease; April W Armstrong
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

4.  Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set.

Authors:  Umut Kalyoncu; Alexis Ogdie; Willemina Campbell; Clifton O Bingham; Maarten de Wit; Dafna D Gladman; Philip Mease; Ingrid Steinkoenig; Vibeke Strand; Victoria G Riese; Ana-Maria Orbai
Journal:  RMD Open       Date:  2016-03-03

5.  Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?

Authors:  Thomas Patton; Laura Bojke; Matthew Walton; Andrea Manca; Philip Helliwell
Journal:  Clin Rheumatol       Date:  2017-06-13       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.